• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Tanzisertib Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754677

MBS5754677 is an inhibitor targeting Tanzisertib. Tanzisertib (CC-930) is a potent inhibitor of JNK1/2/3 (IC50s: 61/7/6nM). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Tanzisertib, Inhibitor
Full Product Name
Tanzisertib
Product Synonym Names
CC-930
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
448.44
Solubility
DMSO: 33mg/mL (73.59mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C21H23F3N6O2
SMILES
O[C@H]1CC[C@H](NC2=NC=C3N=C(NC4=C(F)C=C(F)C=C4F)N([C@@H]5COCC5)C3=N2)CC1
CAS Number
899805-25-5
Target & IC50
JNK3: ic50 6nM
JNK2: ic50 7nM
JNK1: ic50 61nM
In Vitro
Tanzisertib (10 and 30mg/kg, p.o.) inhibits the production of TNFa by 23% and 77% in the acute rat LPS-induced TNFa production PK-PD model [1]. Tanzisertib (150mg/kg) prevents the development of fibrosis in different models. However, it can also induce the regression of pre-existing fibrosis [3].

Product Categories/Family for Tanzisertib, inhibitor

Product References and Citations for Tanzisertib, inhibitor

Plantevin Krenitsky V, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett. 2012 Feb 1;22(3):1433-8.
Plantevin Krenitsky V, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett. 2012 Feb 1;22(3):1433-8.
Gan LT, et al. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol. 2014 Dec;61(6):1376-84.
Gan LT, et al. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol. 2014 Dec;61(6):1376-84.
Reich N, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment,of dermal fibrosis. Ann Rheum Dis. 2012 May;71(5):737-45.
Reich N, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment,of dermal fibrosis. Ann Rheum Dis. 2012 May;71(5):737-45.
Tavernier SJ, et al. Regulated IRE1-dependent mRNA decay sets the threshold for dendritic cell survival. Nat Cell Biol. 2017 Jun;19(6):698-710.
Tavernier SJ, et al. Regulated IRE1-dependent mRNA decay sets the threshold for dendritic cell survival. Nat Cell Biol. 2017 Jun;19(6):698-710.

Other Notes

Small volumes of Tanzisertib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000